Occurrence and modulation of therapeutic targets of Aurora kinase inhibition in pediatric acute leukemia cells

References

• Pui CH, Jeha S. New therapeutic strategies for the treatment of acute lymphoblastic leukemia. Nat Rev Drug Discov 2007;6:149–165.
   PubMed Web of Science ®Google Scholar
• Stanulla M, Schrappe M. Treatment of childhood acute lymphoblastic leukemia. Semin Hematol 2009;46:52–63.
   PubMed Web of Science ®Google Scholar
• Jeha S. New therapeutic strategies in acute lymphoblastic leukemia. Semin Hematol 2009;46:76–88.
   PubMed Web of Science ®Google Scholar
• Carroll WL, Bhojwani D, Min DJ, et al. Pediatric acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2003:102–131.
   PubMedGoogle Scholar
• Harned TM, Gaynon PS. Relapsed acute lymphoblastic leukemia: current status and future opportunities. Curr Oncol Rep 2008;10: 453–458.
   PubMed Web of Science ®Google Scholar
• Silverman LB. Acute lymphoblastic leukemia in infancy. Pediatr Blood Cancer 2007;49:1070–1073.
   PubMed Web of Science ®Google Scholar
• Ramakers-van Woerden NL, Beverloo HB, Veerman AJP, et al. In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype. Leukemia 2008;18:521–529.
   Web of Science ®Google Scholar
• Carmena M, Earnshaw WC. The cellular geography of Aurora kinases. Nat Rev Mol Cell Biol 2003;4:842–854.
   PubMed Web of Science ®Google Scholar
• Curry J, Angove H, Fazal L, et al. Aurora B kinase inhibition in mitosis. Cell Cycle 2009;8:1921–1929.
   PubMed Web of Science ®Google Scholar
• Li M, Jung A, Ganswindt U, et al. Aurora kinase inhibitor ZM447439 induces apoptosis via mitochondrial pathways. Biochem Pharmacol 2009;79:122–129.
   PubMed Web of Science ®Google Scholar
• Kaestner P, Stolz A, Bastians H. Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells. Mol Cancer Ther 2009;8:2046–2056.
   PubMed Web of Science ®Google Scholar
• Li JJ, Li SA. Mitotic kinases: the key to duplication, segregation and cytokinesis errors, chromosomal instability and oncogenesis. Pharmacol Ther 2006;111:974–986.
   PubMed Web of Science ®Google Scholar
• Yakushijin Y, Hamada M, Yasukawa M. The expression of Aurora-A gene and its significance with tumorigenesis in non-Hodgkin's lymphoma. Leuk Lymphoma 2004;45:1741–1746.
   PubMed Web of Science ®Google Scholar
• Fujita M, Mizuno M, Nagasaka T, et al. Aurora-B dysfunction of multinucleated giant cells in glioma detected by site-specific phosphorylated antibodies. J Neurosurg 2004;101:1012–1017.
   PubMed Web of Science ®Google Scholar
• Gautschi O, Heighway J, Mack PC, et al. Aurora kinases as anticancer drug targets. Clin Cancer Res 2008;14:1639–1648.
   PubMed Web of Science ®Google Scholar
• Slattery SD, Mancini MA, Brinkley BR, et al. Aurora-C kinase supports mitotic progression in the absence of Aurora-B. Cell Cycle 2009;8:2986–2997.
   Web of Science ®Google Scholar
• Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 2009;8:547–566.
   PubMed Web of Science ®Google Scholar
• Katayama H, Brinkley WR, Sen S. The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev 2003; 22:451–464.
   PubMedGoogle Scholar
• Pollard JR, Mortimore JM. Discovery and development of Aurora kinase inhibitors as anticancer agents. J Med Chem 2009; 52:2629–2651.
   PubMed Web of Science ®Google Scholar
• Ikezoe T, Yang J, Nishioka C, et al. A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia. Mole Cancer Ther 2007;6:1851–1857.
   PubMed Web of Science ®Google Scholar
• Moore AS, Blagg J, Linardopoulos S, et al. Aurora kinase inhibitors: novel small molecules with promising activity acute myeloid and Philadelphia-positive leukemias. Leukemia 2010;24:671–678.
   PubMed Web of Science ®Google Scholar
• Howard S, Berdini V, Boulstridge JA, et al. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent Aurora kinase activity. J Med Chem 2009;52:379–388.
   PubMed Web of Science ®Google Scholar
• Narendran A, Ganjavi H, Morson N, et al. Mutant p53 in bone marrow stromal cells increases VEGF expression and supports leukemia cell growth. Exp Hematol 2003;31:693–701.
   PubMed Web of Science ®Google Scholar
• Hawkins LM, Jayanthan AA, Narendran A. Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr-Abl status and imatinib mesylate sensitivity. Pediatr Res 2005;57:430–437.
   PubMed Web of Science ®Google Scholar
• Zhao L, Wientjes G, Au JLS. Evaluation of combination chemotherapy: integration on nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res 2004; 10:7994–8004.
   PubMed Web of Science ®Google Scholar
• Yao Q, Nishiuchi R, Li Q, et al. FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases. Clin Cancer Res 2003;9:4483–4493.
   PubMed Web of Science ®Google Scholar
• Armstrong SA, Kung AL, Mabon ME, et al. Inhibition of FLT3 in MLL: validation of a therapeutic target identified by gene expression based classification. Cancer Cell 2003;3:173–183.
   PubMed Web of Science ®Google Scholar
• Maris JM, Morton CL, Gorlick R, et al. Initial testing of the Aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer 2010;55:26–34.
   PubMed Web of Science ®Google Scholar
• Andrews DF 3rd,Nemunaitis JJ, Singer JW. Recombinant tumor necrosis factor alpha and interleukin 1 alpha increase expression of c-abl protooncogene mRNA in cultured human marrow stromal cells. Proc Natl Acad Sci USA 1989;86:6788–6792.
   PubMed Web of Science ®Google Scholar
• Stirewalt DL, Radich JP. The role of Flt3 in haematopoietic malignancies. Nat Rev Cancer 2003;3:650–665.
   PubMed Web of Science ®Google Scholar
• Levis M, Small D. FLT3: ITDoes matter in leukemia. Leukemia 2003;17:1738–1752.
   PubMed Web of Science ®Google Scholar
• Steelman LS, Franklin RA, Abrams SL, et al. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. Leukemia 2011;25:1080–1094.
   PubMed Web of Science ®Google Scholar
• Walz C, Cross NCP, Van Etten RA, et al. Comparison of mutated ABL1 and JAK2 oncogenes and drug targets in myeloproliferative disorders. Leukemia 2008;22:1320–1334.
   PubMed Web of Science ®Google Scholar
• Soldani C, Scovassi AI. Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis 2002;7:321–328.
   PubMed Web of Science ®Google Scholar
• Ahn MY, Lee J, Na YJ, et al. Mechanism of apicidin-induced cell cycle arrest and apoptosis in human endometrial cancer cells. Chem Biol Interact 2009;179:169–177.
   PubMed Web of Science ®Google Scholar
• Vita M, Henrikkson M. The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol 2006;16:318–330.
   PubMed Web of Science ®Google Scholar
• Scuto A, Kirschbaum M, Kowolik C, et al. The novel histone deacetylase inhibitor, LBH-589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells. Blood 2008;111:5093–5100.
   PubMed Web of Science ®Google Scholar
• Buglio D, Georgakis GV, Hanabuchi S, et al. Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood 2008;12: 1424–1433.
   Web of Science ®Google Scholar
• Kretzner L, Scuto A, Dino PM, et al. Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT and micro-RNA levels. Cancer Res 2011;71:3912–3920.
   PubMed Web of Science ®Google Scholar
• Tang Y, Williams BR, Siegel JJ, et al. Identification of aneuploidy-selective antiproliferative compounds. Cell 2011;144:499–512.
   PubMed Web of Science ®Google Scholar
• Burrows F, Zhang H, Kamal A. Hsp90 activation and cell cycle regulation. Cell Cycle 2004;3:1530–1536.
   PubMed Web of Science ®Google Scholar
• Greil J, Gramatzki M, Burger R, et al. The acute lymphoblastic leukemia cell line SEM with t(4:11) chromosomal rearrangement is biphenotypic and responsive to interleukin-7. Br J Haematol 1994;86:275–283.
   PubMed Web of Science ®Google Scholar
• Freedman MH, Grunberger T, Correa P, et al. Autocrine and paracrine growth control by granulocyte-moncyte colony-stimulating factor of acute lymphoblastic leukemia cells. Blood 1993;81:3068–3075.
   PubMed Web of Science ®Google Scholar
• Jayanthan A, Incoronato A, Singh A, et al. Cytotoxicity, Combinability and biological correlates of ABT-737 against leukemia cells with MLL rearrangement. Pediatr Blood Cancer 2011;56: 353–360.
   PubMed Web of Science ®Google Scholar
• Inaba T, Roberts WM, Shapiro LH, et al. Fusion of the leucine zipper gene HLF to the E2A gene in human acute B-lineage leukemia. Nature 1992;257:531–534.
   Google Scholar
• Matsuo Y, MacLeod RA, Uphoff CC, et al. Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11:9)(q23:p22p23). Leukemia 1997;11:1469–1477.
   PubMed Web of Science ®Google Scholar
• Tang R, Faussat AM, Perrot JY, et al. A new acute lymphoblastic leukaemia cell line BEL-1 with t(4:11)(q21:q23) chromosomal translocation and a unique aberrant p27 transcript. Br J Haematol 2004;126:754–755.
   PubMed Web of Science ®Google Scholar
• Okabe M, Matsushima S, Morioka M, et al. Establishment and characterization of a cell line, TOM-1, derived from a patient with Philadelphia chromosome-positive acute lymphocytic leukemia. Blood 1987;69:990–998.
   PubMed Web of Science ®Google Scholar